The United Kingdom and the United States have reached a landmark trade agreement that will guarantee zero import taxes on British pharmaceutical exports being sold in the US market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has pledged to raise spending on pharmaceuticals through the public health system. This commitment secures that import taxes on these crucial goods will remain at nothing for a duration of the next three years.
This agreement comes after previous statements to dramatically increase duties on patented drug imports, with potential rates floated up to 100%.
"This deal between the United Kingdom strengthens the international landscape for innovative medicines and brings much-needed balance to transatlantic medicine commerce," a statement said.
Economic Impact
Medicines represent one of the the United Kingdom's most significant export categories to the America, which is by far the primary market for large UK drugmakers.
Trade data show that in the one-year period to the end of last September, the UK sold pharmaceutical products valued at billions to the US. This value accounted for a significant portion of total UK exports in that timeframe.
"This agreement safeguards jobs, stimulates investment and sets the stage for the UK to become a global hub for life sciences," a government official commented.
Detailed British Pledges
The deal includes several key commitments from the UK:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it deems new therapies to be prohibitively costly by 25%.
- Higher Drug Budget: There is a target to double overall public funding on treatments from 0.3% of the national economy to 0.6% over the coming ten years.
- Payback Limit: The sum drug companies must return to the NHS to stay within budget will be limited at fifteen percent. In the past, rebates topped 20%.
Recent Tensions
The pact comes amid a ongoing dispute between the pharmaceutical industry and the ministers over medicine costs and NHS adoption.
This friction were intensified by arguments that US customers were charged several times more for the identical medicines than people in the Britain and the EU.
Over the last 18 months, several major pharmaceutical investments in the UK have been halted or scrapped, while substantial investments have been directed toward projects in the United States.
A senior figure publicly accepted that the NHS needed to increase expenditure on medicines, noting that its expenditure on drugs had declined as a proportion of its overall budget over the last ten years.
